相关实验视频
Updated: Jul 25, 2025

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.8K
Nrf2作为治疗点在黑色素瘤中对向疗法的耐药性
Marie Angèle Cucci1, Margherita Grattarola1, Chiara Monge2
1Department of Clinical and Biological Science, University of Turin, Corso Raffaello 30, 10125 Turin, Italy.
Antioxidants (Basel, Switzerland)
|June 28, 2023
概括
在黑色素瘤中,有针对性的治疗耐药性是一个主要的挑战. 这项研究表明,由DUB3控制的抗氧化剂调节剂Nrf2通过调节YAP来驱动抗性,并且抑制Nrf2可以恢复治疗灵敏度.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 皮肤病学 皮肤病学
背景情况:
- 像BRAF抑制剂 (BRAFi) 和MEK抑制剂 (MEKi) 这样的向疗法改善了转移性黑色素瘤的结果.
- 获得对这些疗法的耐药性仍然是一个重大的临床挑战,许多患者在一年内发展出耐药性.
- 与氧化应激相关的机制越来越被认为是这种获得性抵抗的关键驱动因素.
研究的目的:
- 为了研究Nrf2的作用,一个主调节器的抗氧化反应,在黑色素瘤中获得了对BRAFi/MEKi的耐药性.
- 阐明调节Nrf2活动的机制及其与化学抵抗中的癌基因YAP的潜在合作.
- 评估向Nrf2或其调节者的治疗潜力,以克服向治疗的耐药性.
主要方法:
- 使用已建立的体外黑色素瘤模型,对BRAFi,MEKi或双BRAFi/MEKi获得了耐药性.
- 评估了耐药黑色素瘤细胞中的Nrf2蛋白水平和调节.
- 研究了杜比基酶DUB3在控制Nrf2蛋白稳定性的作用.
- 研究了Nrf2与瘤基因YAP表达之间的关系.
- 评估了Nrf2或DUB3抑制对恢复针对性治疗敏感性的影响.
主要成果:
- 发现Nrf2在针对性治疗耐药的黑色素瘤细胞中在翻译后水平上升调节.
- 杜比基因酶DUB3被确定为耐药细胞中Nrf2蛋白稳定的关键调节剂.
- Nrf2被证明可以控制癌基因YAP的表达.
- 直接或通过向DUB3来抑制Nrf2,有效地逆转了BRAFi/MEKi获得的耐药性.
- 这些发现突出了一个涉及Nrf2和YAP的新型抗药机制.
结论:
- Nrf2在调解黑色素瘤中对BRAFi/MEKi的获得性耐药性方面发挥着关键作用,部分是通过对YAP的调节.
- DUB3是稳定Nrf2的关键因素,有助于产生抗药性表型.
- 针对Nrf2/DUB3/YAP轴是一个有希望的治疗策略,以克服针对性黑色素瘤疗法的耐药性.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

